pT3-EF1A-MYC-IRES-lucOS Citations (1)

Originally described in: beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma.
Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, Llovet JM, Merad M, Lujambio A Cancer Discov. 2019 Jun 11. pii: 2159-8290.CD-19-0074. doi: 10.1158/2159-8290.CD-19-0074. PubMed Journal

---

Articles Citing pT3-EF1A-MYC-IRES-lucOS

Articles

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. PubMed

If you have published an article using this material, please email us at to have your article added to this page.